瑞舒伐他汀联合曲美他嗪治疗冠心病稳定型心绞痛患者的临床效果  

Effect of Rosuvastatin combined with Trimetazidine in the treatment of patients with stable angina pectoris of coronary artery disease

作　　者：王恒永 WANG Hengyong(Department of Cardiology,the Second People's Hospital of Xintai City,Tai'an,Shandong 271219,China)

机构地区：[1]新泰市第二人民医院心血管内科,山东泰安271219

出　　处：《医药前沿》2025年第3期51-54,共4页Journal of Frontiers of Medicine

摘　　要：目的 观察瑞舒伐他汀联合曲美他嗪治疗冠心病稳定型心绞痛(SAP)患者的临床效果。方法 选取2021年6月—2023年6月就诊于新泰市第二人民医院的280例SAP患者,采用随机数字表法将其分为对照组和观察组两组,各140例。对照组给予瑞舒伐他汀治疗,观察组使用瑞舒伐他汀联合曲美他嗪治疗,两组均治疗8周。比较两组临床疗效、心功能指标、血管内皮功能、斑块稳定性及不良反应。结果 观察组总有效率、左心室射血分数高于对照组,左心室舒张末期内径及左心室收缩末期内径低于对照组(P<0.05);观察组血清内皮素-1、血清五聚素-3及脂蛋白相关磷脂酶A2、高敏C-反应蛋白水平低于对照组,血清一氧化氮水平高于对照组(P<0.05);两组不良反应总发生率比较,差异无统计学意义(P>0.05)。结论 瑞舒伐他汀联合曲美他嗪可改善心功能,加快血管内皮功能恢复,增强斑块稳定性,且安全性高。Objective To observe the effect of Rosuvastatin combined with Trimetazidine in the treatment of patients with stable angina pectoris(SAP)of coronary artery disease(CAD).Methods A total of 280 patients with SAP who were admitted to the Second People's Hospital of Xintai City from June 2021 to June 2023 were divided into control group and observation group by random number table method,with 140 cases in each group.The control group received Rosuvastatin treatment,while the observation group received a combination of Rosuvastatin and Trimetazidine.Both group treatments lasted for 8 weeks.The comparisons were performed on the clinical efficacy,cardiac function parameters,endothelial function,plaque stability,and adverse events in both groups.Results Compared with the control group,the observation group achieved higher total effective rate and left ventricular ejection fraction,however,the observation group obtained lower left ventricular end-diastolic diameter and left ventricular end-systolic diameter(P<0.05);Furthermore,the levels of serum endothelin-1,pentraxin-3,lipoprotein-associated phospholipaseA2,and high-sensitive C-reactive protein in the control group were lower in the observation group,while the observation group obtained higher serum nitric oxide level compared with the control group(P<0.05).The total incidence of adverse events in the two groups was comparable,which showed no statistical difference(P>0.05).Conclusions The combination of Rosuvastatin and Trimetazidine is highly effective in improving cardiac function,promoting endothelial function recovery,and enhancing plaque stability in patients with SAP,which also has high safety.

关 键 词：冠心病 稳定型心绞痛 瑞舒伐他汀 曲美他嗪 心功能 血管内皮功能 斑块稳定性 临床效果 

分 类 号：R541[医药卫生—心血管疾病]